Copyright tradingview
agilon health inc AGL, AGL is expected to show a fall in quarterly revenue when it reports results on November 4 for the period ending September 30 2025 The Westerville Ohio-based company is expected to report a 1.9% decrease in revenue to $1.423 billion from $1.45 billion a year ago, according to the mean estimate from 16 analysts, based on LSEG data. LSEG's mean analyst estimate for agilon health inc is for a loss of 16 cents per share. The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 14 "hold" and 2 "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for agilon health inc is $1.35, about 40.7% above its last closing price of $0.80
